DaVita Inc. (NYSE:DVA) Shares Sold by Strategic Advocates LLC

Strategic Advocates LLC cut its holdings in DaVita Inc. (NYSE:DVA) by 27.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,437 shares of the company’s stock after selling 539 shares during the period. Strategic Advocates LLC’s holdings in DaVita were worth $215,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Mediolanum International Funds Ltd bought a new stake in shares of DaVita during the fourth quarter valued at approximately $868,000. SteelPeak Wealth LLC acquired a new position in DaVita during the 4th quarter worth $1,045,000. Nilsine Partners LLC grew its stake in shares of DaVita by 0.8% in the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock worth $1,669,000 after purchasing an additional 92 shares in the last quarter. KBC Group NV increased its stake in DaVita by 0.8% during the 4th quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after buying an additional 2,636 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of DaVita by 39.7% in the 4th quarter. Blue Trust Inc. now owns 461 shares of the company’s stock worth $76,000 after acquiring an additional 131 shares during the period. Institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on DVA shares. Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Truist Financial lifted their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, DaVita has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Stock Performance

Shares of DVA opened at $176.62 on Friday. The company has a 50-day moving average of $159.50 and a two-hundred day moving average of $154.77. The stock has a market cap of $14.48 billion, a price-to-earnings ratio of 19.05, a PEG ratio of 0.85 and a beta of 0.92. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a one year low of $107.74 and a one year high of $178.75.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.85 earnings per share. On average, equities research analysts expect that DaVita Inc. will post 9.71 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.